Pulmonary Arterial Hypertension (PAH) Drugs Market by Route of Administration, Action Mechanism, and Geography - Forecast and Analysis 2023-2027

Published: Mar 2023 Pages: 172 SKU: IRTNTR75157

Pulmonary Arterial Hypertension (PAH) Drugs Market

The pulmonary arterial hypertension (PAH) drugs market size is estimated to grow at a CAGR of 6.62% between 2022 and 2027. The pulmonary arterial hypertension drugs market size is forecast to increase by USD 2.08 billion. The growth of the market depends on several factors, including the growing prevalence of PAH, the growing geriatric population, and the increasing risk factors for cardiovascular diseases.

This pulmonary arterial hypertension (PAH) drugs market report extensively covers market segmentation by route of administration (oral, injectable, and inhalation), action mechanism (prostacyclin analogs, endothelin receptor antagonists (ERAS), phosphodiesterase (PDE) inhibitors, and soluble guanylate cyclase stimulators (SGCSS)), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the Size of the Pulmonary Arterial Hypertension (PAH) Drugs Market During the Forecast Period?

To learn more about this report, View Report Sample

Pulmonary Arterial Hypertension (PAH) Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

The growing prevalence of PAH is notably driving the market growth, although factors such as a shortage of healthcare professionals may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Pulmonary Arterial Hypertension Drugs Market Driver

Growing prevalence of PAH is the key factor driving the growth of the global pulmonary arterial hypertension drugs market. With the prevalence of PAH disease, the market for PAH drugs is expanding. During the forecast period, rising prevalence of PAH disease and associated hospitalizations for treatment are expected to increase the demand for the corresponding drugs. When PAH occurs, the small arteries in the lungs thicken and narrow. Blood flow through the lungs is blocked by PAHs. As a result, blood pressure in the lungs increases, making it difficult for the heart to pump blood through narrowed arteries. A person's heart gradually loses its capacity to pump blood effectively throughout the body.

Women between the ages of 30 and 60 are most affected by PAH. According to the National Organization for Rare Disorders (NORD), women are three to five times more likely to develop PAH than men. Moreover, according to a study by the National Organization for Rare Disorders, around 500-1,000 new cases of PAH are recorded in the US every year or 1-2 cases per billion people. Thus, the growing incidence of PAH is expected to drive the growth of the global PAH drugs market during the forecast period.

Significant Pulmonary Arterial Hypertension Drugs Market Trends

Increasing awareness regarding PAH is the primary trend in the global pulmonary arterial hypertension drugs market. With the prevalence of PAH disease, the market for PAH drugs is expanding. During the forecast period, rising prevalence of PAH disease and associated hospitalizations for treatment are expected to increase the demand for the corresponding drugs. When PAH occurs, the small arteries in the lungs thicken and narrow. Blood flow through the lungs is blocked by PAHs. As a result, blood pressure in the lungs increases, making it difficult for the heart to pump blood through narrowed arteries. There are numerous treatments on the market that aid in reducing the progression of diseases and enhancing the quality of life.

Additionally, the approval of a small number of potent medications and the existence of a promising pipeline are some key elements that will propel the growth of the global PAH drugs market during the forecast period. Additionally, favorable government policies will help in increasing the demand for PAH treatments, which in turn will drive the growth of the global PAH drugs market during the forecast period.

Major Pulmonary Arterial Hypertension Drugs Market Challenge

Shortage of healthcare professionals is major challenge to the growth of the global pulmonary arterial hypertension drugs market. Our network of medical facilities, laboratories, and diagnostic centers spans the globe. The growing world population has increased the burden of running an effective healthcare system. The growth of the healthcare industry is hampered by several factors, such as high infrastructure, machinery and equipment costs, and lack of qualified staff. According to the WHO, there will be 12.9 billion fewer healthcare workers in the world by 2035 than in 2021.

Moreover, several factors, such as an aging workforce, a decline in the number of people entering the field, early retirements, inadequate training, and increased demands from an aging and growing population, all these factors will lead to a shortage of healthcare professionals. Thus, a shortage of healthcare professionals can become a major challenge to the growth of the global PAH drugs market during the forecast period.

Key Pulmonary Arterial Hypertension Drugs Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Pulmonary Arterial Hypertension Drugs Market Customer Landscape

Who are the Major Pulmonary Arterial Hypertension (PAH) Drugs Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Aerami Therapeutics Holdings Inc.: The company offers pulmonary arterial hypertension drug solutions such as Orphan. Also, this segment focuses on developing inhaled therapies to treat severe respiratory and chronic diseases.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • Asklepion Pharmaceuticals LLC
  • AstraZeneca Plc
  • Bayer AG
  • Daiichi Sankyo Co. Ltd.
  • Dr Reddys Laboratories Ltd.
  • Eiger BioPharmaceuticals Inc.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Johnson and Johnson Services Inc.
  • Lupin Ltd.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • United Therapeutics Corp.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Pulmonary Arterial Hypertension (PAH) Drugs Market?

The market share growth by the oral segment will be significant during the forecast period. Oral administration comprises tablets and suspensions, and tablets can be branched as film-coated tablets and extended-release tablets. Since the study of widespread animal and human efficacy and safety is not required in these formulations, the market segment is likely to witness growth during the forecast period.

Get a glance at the market contribution of various segments View the PDF Sample

The oral segment was valued at USD 2.93 billion in 2017 and continued to grow until 2021. There are different oral drugs available for the treatment of PAH. The endothelin receptor antagonists (ERAs), bosentan and sitaxentan, and sildenafil are all used as oral medications to treat symptomatic, moderate-to-severe PAH. For instance, Ambrisentan is a brand-new oral ERA that selectively targets the ET(A) receptor and has a higher ET receptor affinity than bosentan. Ambrisentan (5 or 10 mg/day) has been shown to be secure and efficient in placebo-controlled, randomized clinical trials (RCTs). Similarly, Bosentan, an oral dual ETA and ETB receptor antagonist increase exercise tolerance and cardiopulmonary hemodynamics in PAH patients. Thus, the growing use of oral drugs to treat PAH is expected to drive the growth of the oral administration segment in the global PAH drugs market during the forecast period.

Which are the Key Regions for the Pulmonary Arterial Hypertension (PAH) Drugs Market?

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 45% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. North America dominates the global PAH drugs market and will hold the largest revenue share in 2022. A substantial portion of the market in focus is attributable to the developed healthcare systems in the US and Canada that make access to cutting-edge therapeutics easier. In addition, increasing awareness, high diagnostic rates, and favourable government initiatives are driving market growth in the region. Regional market expansion is also supported by a well-designed reward structure and the presence of key players. The need for advanced medical facilities to treat pulmonary arterial hypertension is driven by the rising prevalence and high diagnosis rates of infectious and chronic diseases in this region.  

The outbreak of COVID-19 in 2020 significantly led to a decline in demand for PAH treatments in North America. However, the lockdowns were lifted in the second half of 2020 owing to large-scale vaccination drives across North America. This led to the resumption of operations in clinics and hospitals that offer PAH treatments, which increased the demand for PAH drugs in the first half of 2021. Such factors are expected to open up new opportunities for PAH treatments and will drive the growth of the PAH drugs market in North America during the forecast period.

Segment Overview

The pulmonary arterial hypertension drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • Rout of Administration Outlook (USD billion, 2017 - 2027)
    • Oral
    • Injectable
    • Inhalation
  • Action Mechanism Outlook (USD billion, 2017 - 2027)
    • Prostacyclin analogs
    • Endothelin receptor antagonists (ERAs)
    • Phosphodiesterase (PDE) inhibitors
    • Soluble guanylate cyclase stimulators (SGCSs)
  • Region Outlook (USD billion, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • ROW
      • Argentina
      • Australia
      • Rest of the world

Pulmonary Arterial Hypertension (PAH) Drugs Market Scope

Report Coverage

Details

Page number

172

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 6.62%

Market growth 2023-2027

USD 2.08 billion

Market structure

Fragmented

YoY growth 2022-2023(%)

5.94

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 45%

Key countries

US, Canada, UK, Germany, and Japan

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Aerami Therapeutics Holdings Inc., Aerovate Therapeutics Inc., Alembic Pharmaceuticals Ltd., Asklepion Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eiger BioPharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Reata Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corp., and Viatris Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View the PDF sample

What are the Key Data Covered in this Pulmonary Arterial Hypertension Drugs Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the pulmonary arterial hypertension drugs market between 2023 and 2027
  • Precise estimation of the size of the pulmonary arterial hypertension drugs market size and its contribution of the market in focus to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of pulmonary arterial hypertension drugs market vendors

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Action Mechanism
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global Pulmonary Arterial Hypertension Drugs Market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global Pulmonary Arterial Hypertension Drugs Market 2017 - 2021 ($ billion)
    • 4.2 Route of Administration Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Route of Administration Segment 2017 - 2021 ($ billion)
    • 4.3 Action Mechanism Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Action Mechanism Segment 2017 - 2021 ($ billion)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Route of Administration

    • 6.1 Market segments
      • Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
    • 6.2 Comparison by Route of Administration
      • Exhibit 32: Chart on Comparison by Route of Administration
      • Exhibit 33: Data Table on Comparison by Route of Administration
    • 6.3 Oral - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Oral - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 35: Data Table on Oral - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 36: Chart on Oral - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Oral - Year-over-year growth 2022-2027 (%)
    • 6.4 Injectable - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Injectable - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 39: Data Table on Injectable - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 40: Chart on Injectable - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Injectable - Year-over-year growth 2022-2027 (%)
    • 6.5 Inhalation - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Inhalation - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 43: Data Table on Inhalation - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 44: Chart on Inhalation - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Inhalation - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by Route of Administration
      • Exhibit 46: Market opportunity by Route of Administration ($ billion)
      • Exhibit 47: Data Table on Market opportunity by Route of Administration ($ billion)

    7 Market Segmentation by Action Mechanism

    • 7.1 Market segments
      • Exhibit 48: Chart on Action Mechanism - Market share 2022-2027 (%)
      • Exhibit 49: Data Table on Action Mechanism - Market share 2022-2027 (%)
    • 7.2 Comparison by Action Mechanism
      • Exhibit 50: Chart on Comparison by Action Mechanism
      • Exhibit 51: Data Table on Comparison by Action Mechanism
    • 7.3 Prostacyclin analogs - Market size and forecast 2022-2027
      • Exhibit 52: Chart on Prostacyclin analogs - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 53: Data Table on Prostacyclin analogs - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 54: Chart on Prostacyclin analogs - Year-over-year growth 2022-2027 (%)
      • Exhibit 55: Data Table on Prostacyclin analogs - Year-over-year growth 2022-2027 (%)
    • 7.4 Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027
      • Exhibit 56: Chart on Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 57: Data Table on Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 58: Chart on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2022-2027 (%)
      • Exhibit 59: Data Table on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2022-2027 (%)
    • 7.5 Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027
      • Exhibit 60: Chart on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 61: Data Table on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 62: Chart on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2022-2027 (%)
      • Exhibit 63: Data Table on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2022-2027 (%)
    • 7.6 Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027
      • Exhibit 64: Chart on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 65: Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 66: Chart on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2022-2027 (%)
      • Exhibit 67: Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2022-2027 (%)
    • 7.7 Market opportunity by Action Mechanism
      • Exhibit 68: Market opportunity by Action Mechanism ($ billion)
      • Exhibit 69: Data Table on Market opportunity by Action Mechanism ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 71: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 72: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 73: Chart on Geographic comparison
      • Exhibit 74: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 UK - Market size and forecast 2022-2027
      • Exhibit 95: Chart on UK - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 96: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 97: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 98: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.9 Germany - Market size and forecast 2022-2027
      • Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.10 Canada - Market size and forecast 2022-2027
      • Exhibit 103: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 104: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 105: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 106: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.11 Japan - Market size and forecast 2022-2027
      • Exhibit 107: Chart on Japan - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 108: Data Table on Japan - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 109: Chart on Japan - Year-over-year growth 2022-2027 (%)
      • Exhibit 110: Data Table on Japan - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 111: Market opportunity by geography ($ billion)
      • Exhibit 112: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 113: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 115: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 116: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 117: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 118: Matrix on vendor position and classification
            • 12.3 Aerami Therapeutics Holdings Inc.
              • Exhibit 119: Aerami Therapeutics Holdings Inc. - Overview
              • Exhibit 120: Aerami Therapeutics Holdings Inc. - Product / Service
              • Exhibit 121: Aerami Therapeutics Holdings Inc. - Key offerings
            • 12.4 Asklepion Pharmaceuticals LLC
              • Exhibit 122: Asklepion Pharmaceuticals LLC - Overview
              • Exhibit 123: Asklepion Pharmaceuticals LLC - Product / Service
              • Exhibit 124: Asklepion Pharmaceuticals LLC - Key offerings
            • 12.5 AstraZeneca Plc
              • Exhibit 125: AstraZeneca Plc - Overview
              • Exhibit 126: AstraZeneca Plc - Product / Service
              • Exhibit 127: AstraZeneca Plc - Key news
              • Exhibit 128: AstraZeneca Plc - Key offerings
            • 12.6 Bayer AG
              • Exhibit 129: Bayer AG - Overview
              • Exhibit 130: Bayer AG - Business segments
              • Exhibit 131: Bayer AG - Key news
              • Exhibit 132: Bayer AG - Key offerings
              • Exhibit 133: Bayer AG - Segment focus
            • 12.7 Daiichi Sankyo Co. Ltd.
              • Exhibit 134: Daiichi Sankyo Co. Ltd. - Overview
              • Exhibit 135: Daiichi Sankyo Co. Ltd. - Business segments
              • Exhibit 136: Daiichi Sankyo Co. Ltd. - Key news
              • Exhibit 137: Daiichi Sankyo Co. Ltd. - Key offerings
              • Exhibit 138: Daiichi Sankyo Co. Ltd. - Segment focus
            • 12.8 Eiger BioPharmaceuticals Inc.
              • Exhibit 139: Eiger BioPharmaceuticals Inc. - Overview
              • Exhibit 140: Eiger BioPharmaceuticals Inc. - Product / Service
              • Exhibit 141: Eiger BioPharmaceuticals Inc. - Key offerings
            • 12.9 Gilead Sciences Inc.
              • Exhibit 142: Gilead Sciences Inc. - Overview
              • Exhibit 143: Gilead Sciences Inc. - Product / Service
              • Exhibit 144: Gilead Sciences Inc. - Key news
              • Exhibit 145: Gilead Sciences Inc. - Key offerings
            • 12.10 GlaxoSmithKline Plc
              • Exhibit 146: GlaxoSmithKline Plc - Overview
              • Exhibit 147: GlaxoSmithKline Plc - Business segments
              • Exhibit 148: GlaxoSmithKline Plc - Key news
              • Exhibit 149: GlaxoSmithKline Plc - Key offerings
              • Exhibit 150: GlaxoSmithKline Plc - Segment focus
            • 12.11 Johnson and Johnson Services Inc.
              • Exhibit 151: Johnson and Johnson Services Inc. - Overview
              • Exhibit 152: Johnson and Johnson Services Inc. - Business segments
              • Exhibit 153: Johnson and Johnson Services Inc. - Key news
              • Exhibit 154: Johnson and Johnson Services Inc. - Key offerings
              • Exhibit 155: Johnson and Johnson Services Inc. - Segment focus
            • 12.12 Lupin Ltd.
              • Exhibit 156: Lupin Ltd. - Overview
              • Exhibit 157: Lupin Ltd. - Product / Service
              • Exhibit 158: Lupin Ltd. - Key news
              • Exhibit 159: Lupin Ltd. - Key offerings
            • 12.13 Merck and Co. Inc.
              • Exhibit 160: Merck and Co. Inc. - Overview
              • Exhibit 161: Merck and Co. Inc. - Business segments
              • Exhibit 162: Merck and Co. Inc. - Key news
              • Exhibit 163: Merck and Co. Inc. - Key offerings
              • Exhibit 164: Merck and Co. Inc. - Segment focus
            • 12.14 Novartis AG
              • Exhibit 165: Novartis AG - Overview
              • Exhibit 166: Novartis AG - Business segments
              • Exhibit 167: Novartis AG - Key offerings
              • Exhibit 168: Novartis AG - Segment focus
            • 12.15 Pfizer Inc.
              • Exhibit 169: Pfizer Inc. - Overview
              • Exhibit 170: Pfizer Inc. - Product / Service
              • Exhibit 171: Pfizer Inc. - Key news
              • Exhibit 172: Pfizer Inc. - Key offerings
            • 12.16 Teva Pharmaceutical Industries Ltd.
              • Exhibit 173: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 174: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 175: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 176: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 177: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 12.17 United Therapeutics Corp.
              • Exhibit 178: United Therapeutics Corp. - Overview
              • Exhibit 179: United Therapeutics Corp. - Product / Service
              • Exhibit 180: United Therapeutics Corp. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 181: Inclusions checklist
                • Exhibit 182: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 183: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 184: Research methodology
                • Exhibit 185: Validation techniques employed for market sizing
                • Exhibit 186: Information sources
              • 13.5 List of abbreviations
                • Exhibit 187: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              pulmonary arterial hypertension drugs market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis